Aktie APHB AMPLIPHI BIOSCIENCES CORP
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren
Inaktiver Wert

Andere Sprachen Ampliphi Biosciences Corp Nyse

Aktien

APHB

US03211P2020

APHB

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Armata Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Armata Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Armata Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023
Armata Pharmaceuticals Secures $35 Million Credit Agreement From Innoviva Unit
Armata Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Armata Pharmaceuticals Announces Presentation of Topline Data from SWARM-P.a. Clinical Study at the North American Cystic Fibrosis Conference
Armata Pharmaceuticals, Inc. Announces First Patient Dosed in the Phase 2A Portion of the Phase 1b/2a 'Disarm' Study of Ap-Sa02 in Adults with Bacteremia Due to Staphylococcus Aureus
Armata Pharmaceuticals, Inc. Announces Executive Changes
Armata Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Armata Pharmaceuticals, Inc. Announces Executive Changes
Armata Pharmaceuticals, Inc. Announces Deborah L. Birx to Board of Directors
Top Premarket Gainers
Armata Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
Armata Pharmaceuticals, Inc. Announces Executive Changes
Armata Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt
Armata Pharmaceuticals Says Phase 1b/2a Trial of AP-PA02 Shows Drug 'Well-Tolerated' -- Shares Rise Pre-Bell
Armata Pharmaceuticals, Inc. Announces Positive Topline Data from Phase 1b/2a SWARM-P.a. Clinical Trial of Inhaled AP-PA02 in Patients with Cystic Fibrosis
Armata Pharmaceuticals Announces Completion of its Phase 1b/2a 'SWARM-P.a.' Study of Inhaled AP-PA02 in Cystic Fibrosis Subjects with Chronic Pulmonary Pseudomonas aeruginosa Infection
Armata Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
Armata Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A2PKLC Aktie
  4. APHB Aktie
  5. Nachrichten Ampliphi Biosciences Corp
  6. Andere Sprachen